Clinical and pathologic features associated with PD-L1 (SP142) expression in stromal tumor-infiltrating immune cells of triple-negative breast carcinoma

[1]  Amy M. Sitapati,et al.  Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  E. Winer,et al.  Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer , 2020, Clinical Cancer Research.

[3]  M. Kurosumi,et al.  Clinicopathological values of PD-L1 expression in HER2-positive breast cancer , 2019, Scientific Reports.

[4]  Akintunde Akinleye,et al.  Immune checkpoint inhibitors of PD-L1 as cancer therapeutics , 2019, Journal of Hematology & Oncology.

[5]  Xue Qin,et al.  Positive correlation between programmed death ligand-1 and p53 in triple-negative breast cancer , 2019, OncoTargets and therapy.

[6]  V. Reuter,et al.  PD-L1 Expression in Urothelial Carcinoma With Predominant or Pure Variant Histology , 2019, The American journal of surgical pathology.

[7]  G. Curigliano,et al.  Recent advances in triple negative breast cancer: the immunotherapy era , 2019, BMC Medicine.

[8]  F. Bertucci,et al.  Genomic characterization of metastatic breast cancers , 2019, Nature.

[9]  Z. Zeng,et al.  Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape , 2019, Molecular Cancer.

[10]  Quirine F. Manson,et al.  Frequent discordance in PD-1 and PD-L1 expression between primary breast tumors and their matched distant metastases , 2018, Clinical & Experimental Metastasis.

[11]  L. Pusztai,et al.  Immunological differences between primary and metastatic breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[13]  B. Taylor,et al.  The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers. , 2018, Cancer cell.

[14]  J. Allison,et al.  Fundamental Mechanisms of Immune Checkpoint Blockade Therapy. , 2018, Cancer discovery.

[15]  F. Wang,et al.  CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia , 2018, Cancer.

[16]  A. Schneeweiss,et al.  nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  John M S Bartlett,et al.  Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. , 2018, Archives of pathology & laboratory medicine.

[19]  Steven J. M. Jones,et al.  Comprehensive Characterization of Cancer Driver Genes and Mutations , 2018, Cell.

[20]  C. Sotiriou,et al.  Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  Ahmet Zehir,et al.  Reliable Pan-Cancer Microsatellite Instability Assessment by Using Targeted Next-Generation Sequencing Data. , 2017, JCO precision oncology.

[22]  Donavan T. Cheng,et al.  Mutational Landscape of Metastatic Cancer Revealed from Prospective Clinical Sequencing of 10,000 Patients , 2017, Nature Medicine.

[23]  Minghui Zhang,et al.  Expression of PD-L1 and prognosis in breast cancer: a meta-analysis , 2017, Oncotarget.

[24]  S. Tyldesley,et al.  Survival with metastatic breast cancer based on initial presentation, de novo versus relapsed , 2017, Breast Cancer Research and Treatment.

[25]  Carsten Denkert,et al.  Clinical relevance of host immunity in breast cancer: from TILs to the clinic , 2016, Nature Reviews Clinical Oncology.

[26]  J. Joo,et al.  Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer. , 2016, Clinical breast cancer.

[27]  Toby C. Cornish,et al.  PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. , 2016, Human pathology.

[28]  Zhongyu Yuan,et al.  High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer , 2015, Oncotarget.

[29]  Donavan T. Cheng,et al.  Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.

[30]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  L. Pusztai,et al.  PD-L1 Expression Correlates with Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy in Breast Cancer , 2014, Cancer Immunology Research.

[32]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[33]  F. Gao,et al.  Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer , 2014, Breast Cancer Research and Treatment.

[34]  Kai Ye,et al.  MSIsensor: microsatellite instability detection using paired tumor-normal sequence data , 2014, Bioinform..

[35]  P. Sharma,et al.  PD-L1 Expression in Triple-Negative Breast Cancer , 2014, Cancer Immunology Research.

[36]  F. André,et al.  Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumors , 2012, Nature.

[38]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[39]  C. Parise,et al.  Variation in breast cancer subtypes with age and race/ethnicity. , 2008, Critical reviews in oncology/hematology.

[40]  A. Tsodikov,et al.  The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor‐negative, invasive breast cancer: The California Cancer Registry, 1999–2004 , 2008, Cancer.

[41]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[42]  R. Cress,et al.  Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotype , 2007, Cancer.

[43]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[44]  E. Cameron,et al.  The Runx genes: lineage-specific oncogenes and tumor suppressors , 2004, Oncogene.

[45]  K. Shigesada,et al.  Mechanism of leukemogenesis by the inv(16) chimeric gene CBFB/PEBP2B-MHY11 , 2004, Oncogene.

[46]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  W T McGivney,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[48]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[49]  T. Honjo,et al.  Induced expression of PD‐1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. , 1992, The EMBO journal.

[50]  E B Cox,et al.  Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. , 1986, Cancer research.

[51]  P. Fasching,et al.  Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. , 2018, The Lancet. Oncology.

[52]  L. Sarian,et al.  Prognostic significance of PD-L1 and PD-L2 in breast cancer. , 2016, Human pathology.

[53]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[54]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). , 2010, Archives of pathology & laboratory medicine.